KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Travere Therapeutics (TVTX) Return on Capital Employed (2016 - 2025)

Travere Therapeutics' Return on Capital Employed history spans 13 years, with the latest figure at 0.15% for Q4 2025.

  • For Q4 2025, Return on Capital Employed rose 78.0% year-over-year to 0.15%; the TTM value through Dec 2025 reached 0.15%, up 78.0%, while the annual FY2025 figure was 0.14%, 52.0% up from the prior year.
  • Return on Capital Employed reached 0.15% in Q4 2025 per TVTX's latest filing, up from 0.22% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.15% in Q4 2025 to a low of 1.06% in Q3 2024.
  • Average Return on Capital Employed over 5 years is 0.53%, with a median of 0.54% recorded in 2023.
  • Peak YoY movement for Return on Capital Employed: plummeted -47bps in 2024, then skyrocketed 84bps in 2025.
  • A 5-year view of Return on Capital Employed shows it stood at 0.31% in 2021, then tumbled by -88bps to 0.57% in 2022, then decreased by -7bps to 0.61% in 2023, then crashed by -52bps to 0.93% in 2024, then surged by 84bps to 0.15% in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Return on Capital Employed are 0.15% (Q4 2025), 0.22% (Q3 2025), and 0.48% (Q2 2025).